Label Changes for:
Copegus (ribavirin) tablet
March 2010
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2010
ADVERSE REACTIONS
Postmarketing Experience
- Additionally, pure red cell aplasia (PRCA) has been reported with Copegus in combination with Pegasys.

